|
Imports of bulk drugs and intermediates grew 5 per cent in July
|
|
Gireesh Babu, New Delhi
September 06 , 2025
|
|
|
Imports of bulk drugs and intermediates to India registered a growth of 5% in the month of July, 2025, while the cumulative imports for the first four months of the fiscal year witnessed a decline of 3.8%.
The imports during the month of July, stood at $410.41 million, as compared to $391.02 million in the same month of last year. The imports have been declining consecutively for the first three months of the fiscal year, reporting a 2.32% decline in April, 6.3% in May, and 12.36%in the month of June, according to data from the ministry of commerce and industry.
In Rupee terms, imports registered a growth of 8.12% in July, at Rs. 35,343 crore as compared to Rs. 32,687 crore reported in the corresponding month of previous fiscal year. Imports in July, 2024 was a decline of 6.71% compared to the Rs. 35,040 crore during the same month of previous fiscal year.
Quantity of imports grew 6.15% at 45,492 MT during the month, as against 42,856 MT in July, 2024. The imports during July, 2024 was a growth of 3.94% from 41,233 MT reported in the month of July, 2023.
Import growth for the first four months of the fiscal year reported a decline of 3.8% to $1.49 billion, as compared to $1.55 billion imports during the same period of previous fiscal year. The imports during April to July, 2024 was around 3% growth compared to $1.5 billion during the same period a year ago.
In Rupee terms, imports during April to July, 2025 witnessed a decline of 1.28% to Rs. 12,814 crore, as compared to Rs. 12,980 crore reported during April to July, 2024. Imports during April to July, 2024 was a growth of 5.30% from Rs. 12,328 crore registered in the same period of previous fiscal year.
In terms of quantity, the first four months of the current fiscal year reported a growth of 2.7% at 1,72,415 MT as compared to 1,67,876 MT reported from April to July, 2024. The April to July period of 2024 witnessed a growth of 12.95% in terms of quantity, as compared to 1,48,620 MT reported in the same period of FY23.
As reported earlier, the first quarter of FY26, from April to June, 2025, reported a decline of 6.9% in bulk drug imports at $1.08 billion, as compared to $1.16 billion in the same period of previous fiscal year. This is compared to a 8.4% growth in imports reported during April to June, 2024, as compared to the corresponding three months of the previous fiscal year.
The imports of bulk drugs and intermediates during the fiscal year 2024-25 reported a growth of 1.8 per cent during the fiscal year 2024-25, even as the quantity has gone up almost 9.3 per cent as compared to the same period a year ago, according to official data.
According to data from the Ministry of Commerce and Industry, the imports during FY 2024-25 stood at $4.65 billion, as compared to $4.55 billion in FY 2023-24. This is compared to a marginal decline reported in the FY 2023-24, as against the $4.51 billion imports reported during FY 2022-23.
The Central government has been emphasising on reducing the imports of essential pharmaceutical raw materials such as bulk drugs, drug intermediates and key starting materials, among others, and has initiated various incentive schemes to support domestic production of these materials.
The Department of Pharmaceuticals has been promoting production of pharma raw materials in the country, including through a production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates and active pharmaceutical ingredients (APIs) in the country, to support the industry in various aspects regarding ease of doing business and availing the benefits of the Scheme.
It has also announced schemes to promote bulk drug parks in the country, as part of its efforts to promote domestic manufacturing of pharma ingredients.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|